Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions
Sign Up to like & getrecommendations! Published in 2025 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2025.2532446
Abstract: ABSTRACT Introduction The addition of the anti-CD38 monoclonal antibody isatuximab to standard therapies is transforming the care of patients with newly diagnosed multiple myeloma (NDMM), as previously seen in the relapsed/refractory setting. This is particularly… read more here.
Keywords: myeloma current; multiple myeloma; treatment; isatuximab treatment ... See more keywords
The Genetic and Molecular Drivers of Multiple Myeloma: Current Insights, Clinical Implications, and the Path Forward
Sign Up to like & getrecommendations! Published in 2024 at "Pharmacogenomics and Personalized Medicine"
DOI: 10.2147/pgpm.s350238
Abstract: Background Multiple myeloma (MM) is a hematological malignancy characterized by the clonal proliferation of malignant plasma cells within the bone marrow. The disease’s complexity is underpinned by a variety of genetic and molecular abnormalities that… read more here.
Keywords: myeloma current; multiple myeloma; drivers multiple; genetic molecular ... See more keywords
Kinase Inhibition in Multiple Myeloma: Current Scenario and Clinical Perspectives
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics14091784
Abstract: Multiple myeloma (MM) is a blood cell neoplasm characterized by excessive production of malignant monoclonal plasma cells (activated B lymphocytes) by the bone marrow, which end up synthesizing antibodies or antibody fragments, called M proteins,… read more here.
Keywords: inhibition multiple; myeloma; current scenario; kinase inhibition ... See more keywords